Anivive Receives NIAID Contract Worth Up to $33M to Progress Valley Fever Vaccine
LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ -- Anivive Lifesciences Inc, a One Health technology company today announced that the National...
Vaccine
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
“NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy”; “Novel Anti-Viral Could Boost a US$3 Billion Market” – Conclude Two Independent Research Reports on NanoViricides
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.,...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone...
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc....
FendX Appoints Dr. Rohit Ramchandani, an Accomplished Public Health Expert, as Advisor
Dr. Ramchandani is a global expert in public health, infectious disease control, and policy implementation.He served as an advisor for...
Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure to boost the market growth, Technavio
NEW YORK, July 30, 2024 /PRNewswire/ -- The global clinical trial management system (CTMS) market size is estimated to grow by...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74...
Versatope Receives Grants to Support Malaria Vaccine Development
LOWELL, Mass., July 29, 2024 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today it has...
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
- This Version Removes the Use of 'Presentation' from the Prior-issued Headline -- Linea™ IVT Platform Delivers All The Benefits...
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
- Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE...
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary...
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go...
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of...
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...
Press Release: Online availability of Sanofi’s half-year financial report for 2024
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report...